CRDF — Cardiff Oncology, Inc.

Summary of Cardiff Oncology Q4 2024 Earnings Call

1. Key Financial Results and Metrics:

• Cash and short-term investments as of December 31, 2024, totaled $91.7 million, bolstered by a $40 million capital raise completed in December.
• Operating cash burn for Q4 2024 was $10.3 million, consistent with previous quarters.
• Current cash resources are projected to sustain operations into Q1 2027.

2. Strategic Updates and Business Highlights:

• Cardiff Oncology reported encouraging initial data from the CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a 64% overall response rate (ORR) in the 30 mg dose group compared to 33% in the control arm.
• The trial has dosed over 380 patients across various studies, with a favorable safety profile noted for onvansertib, differentiating it from previous PLK1 inhibitors.
• The company strengthened its intellectual property portfolio with a new patent covering the use of onvansertib in combination with bevacizumab for KRAS-mutated mCRC, expiring no earlier than 2043.
• Two preclinical posters presented at the San Antonio Breast Cancer Symposium highlighted the potential of onvansertib in breast cancer therapies.

3. Forward Guidance and Outlook:

• Cardiff expects to complete enrollment of the 90 evaluable patients in the CRDF-004 trial within the next few weeks, with additional clinical data anticipated in the first half of 2025.
• The company plans to engage with the FDA to discuss dose selection and trial design for a potential registrational trial (CRDF-005).

4. Bad News, Challenges, or Points of Concern:

• While the initial data is promising, there is uncertainty regarding the timing and maturity of progression-free survival (PFS) data, which may not be available in the first half of 2025.
• Competitive pressures exist from other companies in the mCRC space, notably Pfizer's recent success with encorafenib, which may influence regulatory pathways and market dynamics.

5. Notable Q&A Insights:

• Management indicated that the next data update will aim to provide a more mature analysis than the initial 30-patient data set, but PFS data may still be premature.
• Discussions with the FDA regarding dose selection and trial design are prioritized, with the possibility of adjusting the number of evaluable patients based on emerging data.
• The company is monitoring competitive developments in KRAS-targeted therapies but believes its focus on first-line treatment for a broader patient population differentiates its approach.

Overall, Cardiff Oncology is positioned with a solid financial foundation and promising clinical data, but it faces challenges in demonstrating long-term efficacy and navigating competitive pressures in the oncology landscape.